$17.18
-1.8%CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
CBLL • NASDAQ
| CeriBell, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-53.4M | -40.5M | -29.5M | -37.2M | |
-670K | 1.1M | 847K | 497K | |
12.2M | 5.4M | 2.7M | 7.9M | |
418K | 2M | 477K | 621K | |
633K | -3.2M | -3.7M | -3.9M | |
-40.8M | -35M | -29.2M | -32M | |
INVESTING ACTIVITIES | ||||
-767K | -1.3M | -983K | -516K | |
-210.8M | (0.0) | (0.0) | (0.0) | |
94.2M | 0.0 | 0.0 | 0.0 | |
-755K | -258K | -780K | -883K | |
-118.1M | -1.6M | -1.8M | -1.4M | |
FINANCING ACTIVITIES | ||||
5.4M | 188.9M | 0.0 | 0.0 | |
0.0 | 7.9M | -3.8M | -39K | |
-386K | -304K | 932K | 154K | |
5.1M | 196.5M | -2.8M | 49.8M | |
CASH FLOW SUMMARY | ||||
-153.9M | 159.9M | -33.7M | 16.4M | |
194.4M | 34.5M | 68.2M | 51.8M | |
40.5M | 194.4M | 34.5M | 68.2M | |
-41.6M | -36.4M | -30.1M | -32.5M |
CBLL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 09, 2025 | 2025 |
Continue your CBLL research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.